Literature DB >> 28561688

Novel Therapeutics in Acute Myeloid Leukemia.

Courtney D DiNardo1, Richard M Stone1, Bruno C Medeiros1.   

Abstract

In this review, we focus on three key areas in acute myeloid leukemia (AML) developmental therapeutics: FLT3 inhibitors, IDH inhibitors, and drugs that may be particularly beneficial in secondary AML.

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28561688     DOI： 10.1200/EDBK_175401

Source DB:  PubMed          Journal:  Am Soc Clin Oncol Educ Book        ISSN： 1548-8748


  5 in total

Review 1.  Current and Future Molecular Targets for Acute Myeloid Leukemia Therapy.

Authors:  Shaheedul A Sami; Noureldien H E Darwish; Amanda N M Barile; Shaker A Mousa
Journal:  Curr Treat Options Oncol       Date:  2020-01-13

2.  Patients with FLT3-mutant AML needed to enroll on FLT3-targeted therapeutic clinical trials.

Authors:  Taylor Bucy; John M Zoscak; Motomi Mori; Uma Borate
Journal:  Blood Adv       Date:  2019-12-10

3.  Genome-wide DNA methylome analysis reveals methylation subtypes with different clinical outcomes for acute myeloid leukemia patients.

Authors:  Haiyan Gao; Xin He; Qiang Li; Ying Wang; Yaoyao Tian; Xi Chen; Jinghua Wang; Yan Guo; Wei Wang; Xiaoyun Li
Journal:  Cancer Med       Date:  2020-07-06       Impact factor: 4.452

Review 4.  Advances in targeted therapy for acute myeloid leukemia.

Authors:  Jifeng Yu; Peter Y Z Jiang; Hao Sun; Xia Zhang; Zhongxing Jiang; Yingmei Li; Yongping Song
Journal:  Biomark Res       Date:  2020-05-20

5.  The effectiveness of three different 7 + 3 induction regimes in China: A retrospective analysis in adult patients with acute myeloid leukemia.

Authors:  Peng Lin; Boliang Zhou; Haiying Yao
Journal:  Pak J Med Sci       Date:  2021 Jan-Feb       Impact factor: 1.088
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.